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abstract
 
The voltage-dependent potassium channel, Kv1.3, is modulated by the epidermal growth factor re-
ceptor (EGFr) and the insulin receptor tyrosine kinases. When the EGFr and Kv1.3 are coexpressed in HEK 293
cells, acute treatment of the cells with EGF during a patch recording can suppress the Kv1.3 current within tens of
minutes. This effect appears to be due to tyrosine phosphorylation of the channel, as it is blocked by treatment
with the tyrosine kinase inhibitor erbstatin, or by mutation of the tyrosine at channel amino acid position 479 to
phenylalanine. Previous work has shown that there is a large increase in the tyrosine phosphorylation of Kv1.3
when it is coexpressed with the EGFr. Pretreatment of EGFr and Kv1.3 cotransfected cells with EGF before patch
recording also results in a decrease in peak Kv1.3 current. Furthermore, pretreatment of cotransfected cells with
an antibody to the EGFr ligand binding domain (
 
a
 
-EGFr), which blocks receptor dimerization and tyrosine kinase
activation, blocks the EGFr-mediated suppression of Kv1.3 current. Insulin treatment during patch recording also
causes an inhibition of Kv1.3 current after tens of minutes, while pretreatment for 18 h produces almost total sup-
pression of current. In addition to depressing peak Kv1.3 current, EGF treatment produces a speeding of C-type
inactivation, while pretreatment with the 
 
a
 
-EGFr slows C-type inactivation. In contrast, insulin does not influence
C-type inactivation kinetics. Mutational analysis indicates that the EGF-induced modulation of the inactivation
rate occurs by a mechanism different from that of the EGF-induced decrease in peak current. Thus, receptor ty-
rosine kinases differentially modulate the current magnitude and kinetics of a voltage-dependent potassium channel.
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introduction
 
Receptor tyrosine kinases play essential roles in cell
growth and differentiation, mitogenesis, and cell sig-
naling (Schlessinger and Ullrich, 1992). These mem-
brane receptors dimerize and/or alter their configura-
tion upon ligand binding, resulting in kinase activation
and the autophosphorylation of several COOH-termi-
nal tyrosine residues. The phosphorylation of these res-
idues facilitates the recruitment of specific proteins
containing Src homology 2 domains, which in turn ini-
tiates downstream signaling cascades that affect a di-
verse group of cellular targets via both tyrosine and
serine/threonine protein kinases. In particular, activa-
tion of the epidermal growth factor receptor (EGFr)
 
1
 
and the insulin receptor tyrosine kinases is known to in-
duce activation of PLC
 
g
 
, PLA
 
2
 
, PI-3 kinase and the ras/
MAPK (mitogen-activated protein kinase) pathway (Clark
and Dunlop, 1991; Schlessinger and Ullrich, 1992; Dikic
et al., 1994). Tyrosine kinases, including the EGF and
insulin receptors, are expressed at high levels in the
nervous system, where they exhibit distinct and highly
regionalized patterns of distribution both during devel-
opment and in the adult (Hanley, 1988). In spite of
this, little is known about the signaling functions of ty-
rosine kinases in neurons, although emerging evidence
from several laboratories indicates that ion channels
are among the targets of tyrosine kinases (reviewed by
Siegelbaum, 1994; Jonas and Kaczmarek, 1996). For ex-
ample, in spinal dorsal horn neurons, the activity of
NMDA (
 
N
 
-methyl-
 
d
 
-aspartate) glutamate receptors is
increased by tyrosine kinases and decreased by tyrosine
phosphatases (Wang and Salter, 1994). In 
 
Aplysia
 
 bag
cell neurons, a voltage-dependent cation channel is
regulated by tyrosine phosphorylation, via a pathway in-
volving serine/threonine kinases and phosphatases (Wil-
son and Kaczmarek, 1993), while a calcium and potas-
sium channel, as well as neuropeptide secretion, are
modulated by insulin (Jonas et al., 1996, 1997).
Voltage-dependent potassium (Kv) channels are im-
portant for the generation and regulation of electrical
activity in neurons, as well as for maintaining the rest-
ing membrane potential in excitable and nonexcitable
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Abbreviations used in this paper:
 
 EGFr, epidermal growth factor re-
ceptor; Kv, voltage-dependent potassium.
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cells (reviewed by Hille, 1992). Based on sequence ho-
mology, Kv channels can be divided into several sub-
families; the Kv1 subfamily exhibits sequence homology
to the 
 
Drosophila Shaker 
 
potassium channel (Chandy,
1991; Chandy and Gutman, 1993). One important fea-
ture that distinguishes different Kv channels is their in-
activation kinetics. Inactivation of Kv channels occurs
by two distinct mechanisms. Fast or N-type inactivation
generally occurs with a time constant of a few millisec-
onds via an open channel pore block by the NH
 
2
 
-termi-
nal region of the channel protein (Hoshi et al., 1990).
C-type inactivation usually occurs with a time constant
of hundreds or thousands of milliseconds (Choi et al.,
1991), by a less well defined mechanism that probably
involves a more global change in the channel protein
conformation. Most Kv channels undergo C-type inacti-
vation (although the time constant of inactivation can
vary widely (Lopez-Barneo et al., 1993), while N-type in-
activation is limited to those channels that possess the
appropriate NH
 
2
 
-terminal sequence or are associated
with a 
 
b
 
 subunit containing a similar sequence (Rettig
et al., 1994). 
Studies during the last decade have made it evident
that Kv channels are important targets for modulation
by protein phosphorylation. Most work to date has fo-
cused on modulation by serine/threonine phosphory-
lation (reviewed in Levitan, 1994), but several Kv1 fam-
ily members are also affected directly by tyrosine phos-
phorylation. In particular, Kv1.2 is suppressed by the
tyrosine kinase PYK2 and EGFr (Huang et al., 1993; Lev
et al., 1995; Peralta, 1995) and Kv1.5 is suppressed by
Src (Holmes et al., 1996
 
b
 
), as well as by activation of sev-
eral growth factor receptors (Timpe and Fantl, 1994).
Kv1.3 is phosphorylated directly by nonreceptor ty-
rosine kinases, resulting in suppression of channel ac-
tivity and modulation of channel kinetics (Holmes et
al., 1996
 
a
 
; Fadool et al., 1997). Serine/threonine kinases
can also be involved in the modulatory pathway leading
to Kv channel modulation (Timpe and Fantl, 1994).
In situ hybridization experiments indicate that Kv1
family members are expressed widely in mammalian
brain. One of these channels, Kv1.3, exhibits a particu-
larly selective distribution in the olfactory bulb and ol-
factory cortex as well as in the dentate gyrus of the hip-
pocampus (Kues and Wunder, 1992). Kv1.3 also is the
major Kv channel in T lymphocytes, where it plays an
essential role in cell proliferation and activation by an-
tigens (Lewis and Cahalan, 1990, 1995). We have exam-
ined the modulation of Kv1.3 channels by the EGFr
and insulin receptor tyrosine kinases. Activation of ei-
ther receptor tyrosine kinase decreases the peak Kv1.3
current amplitude. In addition, EGF treatment pro-
duces a speeding of C-type inactivation kinetics, while
insulin treatment does not alter C-type inactivation.
Mutational analysis indicates that different molecular
mechanisms mediate the effects of EGF on current am-
plitude and kinetics. Thus Kv channels are targets for
complex modulation by growth factor receptor tyrosine
kinases.
 
materials and methods
 
Materials
 
Human recombinant EGF and erbstatin were purchased from
Calbiochem Inc. (La Jolla, CA), while insulin and a neutralizing
EGFr antibody were obtained from Upstate Biotechnology Inc.
(Lake Placid, NY). Cell culture reagents were from Gibco Labora-
tories (Grand Island, NY). Other chemicals were from Sigma
Chemical Co. (St. Louis, MO).
 
Channel and Kinase Expression
 
The voltage-gated potassium channel Kv1.3 and the human EGFr
were expressed transiently in HEK 293 cells. HEK 293 cells were
maintained in MEM (12360; Gibco Laboratories) plus 2% peni-
cillin/streptomycin (15140; Gibco Laboratories), and 10% fetal
bovine serum (16000; Gibco Laboratories). Cells were grown to
confluency (7 d), dissociated with trypsin-EDTA (Gibco Labora-
tories) and mechanical trituration, diluted in MEM to a concen-
tration of 
 
z
 
600 cells/
 
m
 
l, and replated on plastic dishes. Cells
were allowed to recover for several days before transfection.
Kv1.3 was expressed using the Invitrogen Corp. (San Diego, CA)
vector pRC-CMV, and the EGFr was expressed in the GW1 vector
(British Biotechnology Ltd., Oxford, UK). In both cases, the pro-
tein coding region was downstream from a cytomegalovirus pro-
moter. The effect of stimulating endogenous insulin receptors
was studied by singly transfecting HEK 293 cells with Kv1.3 and
adding insulin to the medium.
cDNA was introduced into cells with a lipofectamine reagent
(18324; Gibco Laboratories), using standard techniques (Hawley-
Nelson et al., 1993). The lipofectamine and the cDNA(s) were
mixed and allowed to complex for 30-40 min, after which the
cells were transfected with the lipofectamine/cDNA complex for
4–6 h in serum-reduced OptiMEM (Gibco Laboratories) me-
dium. For electrophysiology, cells at 
 
z
 
30–50% density were trans-
fected with a total of 2 
 
m
 
g DNA per 35-mm dish. For biochemis-
try, cells at 
 
z
 
85–95% density were transfected with 10 
 
m
 
g per
60-mm dish (equal amounts of Kv1.3 cDNA and either EGFr or
control vector cDNA). Expression levels after 48–72 h allow the
recording of macroscopic currents from membrane patches and
detection of proteins by immunoprecipitation and Western blotting. 
 
Biochemistry
 
Kv1.3 protein expression was measured using Western blot meth-
ods as described previously (Holmes et al., 1996
 
a
 
). Cells were
harvested 2 d after transfection by lysis in ice-cold lysis buffer. Ly-
sate proteins were separated by SDS-PAGE and electrotrans-
ferred to nitrocellulose blots. These Western blots were then
probed with anti–Kv1.3 antiserum (Cai and Douglass, 1993), and
bound antibody was visualized by enhanced chemiluminescence
(Amersham Corp., Arlington Heights, IL) to measure Kv1.3 pro-
tein expression. Film autoradiograms of Western blots were ana-
lyzed by densitometry using an imaging densitometer (GS-670;
Bio-Rad Laboratories, Richmond, CA).
 
Electrophysiology
 
Macroscopic currents were recorded at room temperature from
cell-attached membrane patches, using an Axopatch 200A (Axon 
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Instruments, Foster City, CA) patch clamp amplifier. To zero the
cell resting membrane potential, the bath solution contained
(mM): 150 KCl, 10 HEPES, 1 EGTA, 0.5 MgCl
 
2
 
, pH 7.5. The pi-
pette solution contained (mM): 30 KCl, 120 NaCl, 2 CaCl
 
2
 
, 10
HEPES, pH 7.5. Pipettes (M15/10; Jencons Glass, Leighton Buz-
zard, UK) typically had resistances of 4–6 M
 
V
 
, and were coated
near the tip with beeswax to reduce the capacitance of the glass.
The standard pulse protocol consisted of voltage steps to 
 
1
 
40
mV for 1 s, at a frequency of one per minute to avoid cumulative
inactivation of Kv1.3 (Marom et al., 1993). Before application of
any drugs, the current amplitude and inactivation rate were al-
lowed to stabilize for 5 min after obtaining a seal. For drug treat-
ment during patch recording, compounds were perfused directly
into the bath through 2-
 
m
 
l capillary tubes. The amplifier output
was filtered at 1–2 kHz, digitized at 2–5 kHz, and stored for later
analysis. Data were collected and stored using software written by
M. Bowlby and S. Marom, and hardware purchased from Mi-
crostar Laboratories, Inc. (Bellevue, WA). Inactivation of macro-
scopic current was fit to the sum of two exponentials by minimiz-
ing the sums of squares (Kupper et al., 1995).
 
Mutagenesis
 
Standard techniques of site-directed mutagenesis using the poly-
merase chain reaction were used to mutate channel tyrosine resi-
dues to phenylalanines. Briefly, the general approach was to
carry out two successive PCR reactions. The first uses the channel
cDNA as the template, with one upstream nonmutagenic oligo-
nucleotide primer, and a downstream mutagenic primer with a
one- to three-base mismatch. The product of this first PCR reac-
tion is used as the upstream primer for the second PCR reaction,
with the downstream primer being nonmutagenic. The amplified
mutant DNA fragment is cut sequentially with flanking restric-
tion enzymes, purified and ligated into the channel backbone
(after the equivalent wild-type region has been removed). All mu-
tants were sequenced to confirm the presence of the mutation
and to detect any sequence errors introduced during the PCR re-
actions. Six tyrosine residues (at four locations) in Kv1.3 lie within
tyrosine kinase consensus phosphorylation sequences and were
targeted for mutation.
 
results
 
Expression of Kv1.3
 
Expression of Kv1.3 in HEK 293 cells produces large
amounts of channel protein, thus allowing both the
biochemical detection of channels using Western blot-
ting techniques and the recording of macroscopic cur-
rents from membrane patches (Bowlby and Levitan,
1995; Holmes et al., 1996
 
a
 
). The expression of Kv1.3, as
measured on a Western blot, is not altered by coexpres-
sion with the EGFr, when compared with coexpression
of Kv1.3 and control vector (Fig. 1 
 
A
 
). Similarly, the ex-
pression of Kv1.3 is not affected by treatment with EGF
(Fig. 1 
 
A
 
) or insulin (Fig. 1 
 
B
 
) for at least 60 min, al-
though insulin treatment for 4 h or longer does reduce
the expression of the channel (data not shown). Quan-
titative densitometric analysis of the Western blots (Ta-
ble I) confirms these conclusions.
 
Suppression of Kv1.3 Current by Activation of Growth
Factor Receptors
 
Previous biochemical experiments have shown that
Kv1.3 is phosphorylated robustly on tyrosine residues
when the channel is coexpressed with the EGFr in HEK
293 cells (Holmes et al., 1996
 
a
 
). To determine whether
acute EGFr activation produces changes in the func-
tional properties of Kv1.3, cotransfected cells were ex-
posed to EGF during a patch recording. The amplitude
of Kv1.3 current in cell-attached patches is decreased
Figure 1. Coexpression of Kv1.3 and the EGFr, or treatment of
Kv1.3-expressing cells with EGF or insulin, does not alter the ex-
pression of Kv1.3 protein. HEK 293 cells were transfected with vec-
tor DNA (Control), or cDNA encoding Kv1.3 and/or EGFr. West-
ern blots of cell lysates were probed with an anti–Kv1.3 antiserum.
(A) Expression of the EGFr, with or without EGF treatment (10
ng/ml, 60 min), does not alter Kv1.3 protein levels. (B) Insulin
treatment of Kv1.3-expressing cells does not alter Kv1.3 protein lev-
els. Cells were treated with 0.1–10 mg/ml insulin for 45 min.
 
table i
 
Effects of Receptor Expression and Activation on Kv1.3 Protein Expression
 
Transfection condition Treatment Relative density units
 
mean 
 
6
 
 SEM
 
Kv1.3 alone Vehicle 1.00 
 
6
 
 0.20
Kv1.3 alone EGF (10 ng/ml) 1.06 
 
6
 
 0.19
Kv1.3 
 
1
 
 EGFr Vehicle 1.04 
 
6
 
 0.13
Kv1.3 
 
1
 
 EGFr EGF (10 ng/ml) 0.92 
 
6
 
 0.16
Kv1.3 alone Vehicle 1.00 
 
6
 
 0.14
Kv1.3 alone Insulin (0.1 
 
m
 
g/ml) 1.25 
 
6
 
 0.15
Kv1.3 alone Insulin (1.0 
 
m
 
g/ml) 1.17 
 
6
 
 0.08
Kv1.3 alone Insulin (10 
 
m
 
g/ml) 1.25 
 
6
 
 0.14
The density of the Kv1.3 band on Western blots (see Fig. 1) is expressed
relative to that for Kv1.3 expressed alone and treated with vehicle. 
 
n
 
 
 
5
 
 4
for each experimental condition. 
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when 10 ng/ml EGF is perfused over the cell (Fig. 2 
 
A
 
).
The suppression by EGF begins within several minutes
and generally continues for as long as the patch sur-
vives, although some patches could be held sufficiently
long for a more-or-less steady state level of current to
be reached (Fig. 2 
 
B
 
). This suppression by EGF applied
during patch recording is blocked by addition of the
tyrosine kinase inhibitor erbstatin, indicating that ty-
rosine kinase activation is necessary for current sup-
pression. Application of erbstatin alone for up to 1 h
has no effect (Fig. 2, 
 
B
 
 and 
 
C
 
).
Longer term manipulation of EGFr activity also leads
to modulation of Kv1.3. When cells are cotransfected
with Kv1.3 and the EGFr, and exposed to EGF (10 ng/
ml) before patch recording, Kv1.3 current is decreased
compared with control cells transfected with Kv1.3 and
vector (Fig. 3 
 
A
 
). On average, this protocol of coexpres-
sion and EGF pretreatment decreases the current re-
corded in a cell-attached patch by approximately half
(Fig. 3 
 
B
 
), somewhat more than acute EGF treatment
(Fig. 2). To test the specificity of this effect, we blocked
EGFr activity with an EGFr antibody (
 
a
 
-EGFr) that se-
lectively inhibits binding of EGF to its receptor and
thus blocks subsequent receptor dimerization and ki-
nase activation (Wu et al., 1989). Pretreatment of cells
coexpressing Kv1.3 and the EGFr with 
 
a
 
-EGFr for 4–12 h
more than reverses the decrease in current (Fig. 3 
 
A
 
),
while pretreatment with inactivated 
 
a
 
-EGFr has no ef-
fect (Fig. 3 
 
B
 
).
It is noteworthy that the Kv1.3 current amplitude in
cotransfected cells exposed to 
 
a
 
-EGFr is more than six
times greater than that in cotransfected cells that were
exposed to EGF before recording (Fig. 3 
 
B
 
). In addi-
tion, the current in 
 
a
 
-EGFr-treated cotransfected cells
is greater than in untreated cells transfected with Kv1.3
and control vector (Fig. 3 
 
B
 
). This result indicates that
an endogenous EGFr expressed in HEK 293 cells may
be partially suppressing current, even in the absence of
coexpressed EGFr or added EGF. Such endogenous
EGFr can be detected in HEK 293 cell lysates, separated
by SDS-PAGE/Western blots and probed with EGFr and
phosphotyrosine-specific antibodies (data not shown).
Insulin treatment also produces a decrease in peak
current amplitude in Kv1.3-transfected cells, presum-
ably due to activation of an endogenous insulin recep-
tor present in HEK 293 cells. Acute treatment of Kv1.3-
transfected cells with 10 
 
m
 
g/ml insulin during a patch
recording suppresses current recorded in cell-attached
patches by approximately half after 10 min of perfusion
(Fig. 4, 
 
A
 
 and 
 
C
 
). Treatment of Kv1.3-transfected cells
with insulin for 5–18 h before patch recording elicits an
even larger decrease in current amplitude when com-
pared with untreated Kv1.3-transfected cells (Fig. 4 
 
B
 
).
Although short term treatment with insulin does not af-
fect channel expression (Fig. 1, Table I), it should be
Figure 2. Acute treatment with EGF during patch recording sup-
presses Kv1.3 current. (A) Cell-attached patch recording from a
cell expressing Kv1.3 and the EGFr. Traces are currents evoked be-
fore (Control) and 20 min after (EGF) beginning to perfuse 10 ng/
ml human recombinant EGF into the bath. Voltage steps to 140
mV were applied once per minute. (B) Time course of suppression
of peak current. Treatment with EGF (10 ng/ml) during patch re-
cording suppresses Kv1.3 current within several minutes. Suppres-
sion is blocked when cells are treated for 1 h before and during re-
cording with 25 mM erbstatin. No effect is observed when erbstatin
alone is applied. Drugs were applied continuously after t 5 0 min.
(C) Mean (6 SEM) inhibition of current in cells exposed to EGF
(10 ng/ml), EGF 1 25 mM erbstatin, or 25 mM erbstatin alone.
n 5 10 with EGF, 4 with EGF 1 erbstatin, and 3 with erbstatin. 
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noted that insulin treatment for 4 h or longer reduces
Kv1.3 protein levels as detected by Western blots (data
not shown). 
 
Modulation of C-Type Inactivation of Kv1.3
 
The kinetics of C-type inactivation of Kv1.3 are altered
markedly by EGFr coexpression and activation. When
cells cotransfected with Kv1.3 and the EGFr are treated
with EGF during patch recording, the inactivation rate
of the current increases (Fig. 5, 
 
A
 
 and 
 
B
 
). No consistent
change in the activation or deactivation rates are found
(data not shown). The change in inactivation rate in-
duced by EGF treatment is blocked when the cell is pre-
treated with the tyrosine kinase inhibitor erbstatin, and
then exposed to EGF together with erbstatin during the
patch recording (Fig. 5 
 
C
 
). Cells cotransfected with Kv1.3
and the EGFr, and pretreated with EGF (10 ng/ml) be-
fore patch recording, also show a faster rate of inactiva-
Figure 3. Longer term manipulation of EGFr activity modulates
Kv1.3 current. All cells were transfected with cDNA encoding
Kv1.3. (A) Cell-attached patch recordings from two cells cotrans-
fected with Kv1.3 and the EGFr, and one cell transfected with
Kv1.3 and control vector. EGFr-cotransfected cells were pretreated
either with 10 ng/ml EGF for 30 min, or overnight with 1 mg/ml
a-EGFr, before patch recording. (B) Current amplitude from cell-
attached patches under varying conditions, normalized to the aver-
age patch current recorded on the same day in cells transfected
with Kv1.3 and control vector. EGF cells were pretreated with 10
ng/ml EGF for 30–60 min, while a-EGFr cells were pretreated with
the antibody for 4–12 h, before patch recording. The a-EGFr was
inactivated (“dead EGFr”) by storing at 48C for 6–8 wk; this anti-
body is stable at 2208C but its neutralizing activity is labile at 48C
(manufacturer’s specifications, confirmed by us). n 5 4 for each
experimental condition; error bars represent the SEM.
Figure 4. Insulin treatment suppresses Kv1.3 current. (A) Cell-
attached patch recording from a cell expressing Kv1.3. Traces are
before (Control) and 10 min after (Insulin) beginning to perfuse
10 mg/ml insulin into the bath. (B) Suppression by insulin pre-
treatment before patch recording. Filled circles are peak current
amplitudes in untreated control cells, while open circles are values
for insulin-pretreated cells. (C) Mean current amplitude for
patches from cells treated with insulin for 4 h or less, normalized to
the values from untreated control cells recorded on the same day.606 Potassium Channel Modulation by Receptor Tyrosine Kinases
tion when compared with Kv1.3 and vector-transfected
controls (Fig. 6, A and B). Pretreatment of these cotrans-
fected cells for 4–14 h with a-EGFr reverses this effect,
and even slows the inactivation rate beyond that of the
control (Fig. 6, A and B). Thus, interruption of tyrosine
kinase activity or EGF binding blocks the EGFr-induced
alteration of the inactivation rate. 
In contrast, neither short (minutes) nor longer (up to
18 h) term insulin treatment of Kv1.3-transfected cells
has a significant effect on the rate of C-type inactivation
of the channel (Fig. 7, A and B). This difference in the
physiological effects of EGFr and insulin receptor stim-
ulation implies that activation of the two receptor ty-
rosine kinases results in different patterns of phosphor-
ylation of Kv1.3.
Two Distinct Actions of EGF on Kv1.3
The speeding of the inactivation rate observed with
EGF perfusion usually occurs simultaneously with the
decrease in current amplitude, although in several ex-
periments the inactivation rate changed before the cur-
rent amplitude decreased, or only the inactivation rate
increased. This led us to hypothesize that the two ef-
fects of EGF might result from distinct molecular
events. The Kv1.3 channel has six putatively internal ty-
rosine residues that reside in consensus sequences for
Figure 5. Application of 10 ng/ml EGF during patch recording
speeds C-type inactivation of Kv1.3. Cells were transfected with
Kv1.3 and EGFr. (A) Traces before (Control) and 30 min after
(EGF) addition of 10 ng/ml EGF to the bath, normalized to the
peak current to better observe the inactivation kinetics. (B) Mean
inactivation rates before and after EGF application. Inactivation
was fit with a weighted double exponential and the two compo-
nents were combined (n 5 10). (C) Mean percent increase in the
inactivation rate for cells treated with EGF (10 ng/ml; n 5 10) or
EGF and erbstatin (25 mM; n 5 4). Erbstatin-treated cells were pre-
treated with the kinase inhibitor for 1–3 h before recording, as well
as during recording. 
Figure 6. Blocking the EGFr with a-EGFr slows the inactivation
rate. (A) Normalized traces from three cells cotransfected with
Kv1.3 and the EGFr and pretreated with no drug (Control), 10 ng/
ml EGF for 30 min, or 1 mg/ml a-EGFr for 12 h. (B) Inactivation
rates of Kv1.3 in cells pretreated as in A, normalized to control
cells recorded on the same day. n 5 4 for each treatment. 607 Bowlby et al.
phosphorylation by tyrosine kinases (Songyang et al.,
1994). Each of these tyrosine residues was mutated to
phenylalanine and the mutant channels were tested for
their responses to EGF. Three of these tyrosines are ad-
jacent to one another at positions 111, 112, and 113,
and thus they were treated as a unit and mutated to-
gether (YYY111–113FFF). Acute EGF treatment of cells
expressing the Kv1.3, Y137F, and Y449F mutant chan-
nels elicits a decrease in peak current and a speeding of
inactivation similar to that of the wild-type channel
(Fig. 8, A and B). A combination mutant of Y449F and
YYY111–113FFF also behaves like the wild-type Kv1.3
with respect to its response to EGF (Fig. 8 C). In con-
trast, Kv1.3 Y479F does not exhibit a change in peak
current in response to EGF, although the effect of EGF
on the inactivation rate is still intact (Fig. 8 D). The av-
erage EGF-induced inhibition of current is significant
(paired t test, P , 0.05) for all the mutant channels ex-
cept for Kv1.3 Y479F (Fig. 8 E), while the increase in
the inactivation rate is significant (paired t test, P ,
0.05) for all the mutant channels (Fig. 8 F). Thus, the
EGF-elicited changes in peak current and inactivation
rate are dissociable and are probably caused by differ-
ent molecular mechanisms.
discussion
We have shown previously that expression and acti-
vation of an EGFr results in increased tyrosine phos-
phorylation of Kv1.3 in HEK 293 cells (Holmes et al.,
1996a). The present results demonstrate that coexpres-
sion of the EGFr and Kv1.3, followed by EGF treatment,
produces a decrease in peak current levels and a speed-
ing of C-type inactivation. Both of these changes are
blocked by pretreatment with a-EGFr, suggesting that
they require receptor dimerization and tyrosine kinase
activation. Insulin treatment produces a similar decrease
in peak current, but no change in C-type inactivation
kinetics, suggesting that the actions of receptor tyrosine
kinases on current amplitude and inactivation kinetics
are distinct and separable. EGF treatment of cotrans-
fected cells suppresses Kv1.3 current and speeds the in-
activation within tens of minutes; both of these effects
are tyrosine kinase dependent because they are blocked
by a tyrosine kinase inhibitor. These two effects of EGF
are also dissociable. Suppression of current by EGF is
dependent upon the presence of Y479 in the channel,
while the change in inactivation kinetics is not altered
by mutating any of the likely targets of tyrosine kinases.
Changes in Kv1.3 amplitude and kinetics induced by
the nonreceptor Src tyrosine kinase also can be attrib-
uted to phosphorylation of different tyrosine residues
(Fadool et al., 1997). Interestingly, Y479 is not required
for the suppression of Kv1.3 current by Src (Fadool et
al., 1997), suggesting that suppression can be achieved
by different molecular mechanisms.
It is clear that ion channels are targets of tyrosine ki-
nases. Tyrosine phosphorylation has a variety of physio-
logical effects on channels, including activation of cal-
cium channels (Peppelenbosch et al., 1991, 1992), poten-
tiation of NMDA receptor-mediated glutamate currents
(Wang and Salter, 1994), stabilization of the assembly
of acetylcholine receptors (Huganir et al., 1984; Wal-
lace et al., 1991; Wallace, 1995), and both potentiation
and inhibition of potassium channel activity (Peppelen-
bosch et al., 1991; Huang et al., 1993; Lev et al., 1995;
Holmes et al., 1996a, 1996b; Jonas et al., 1996; Fadool
et al., 1997). Modulation of ion channels by growth fac-
tor tyrosine kinases often occurs at the level of gene ex-
pression and protein synthesis, as several studies have
reported effects on mRNA levels over several days (Fanger
et al., 1995; Lesser and Lo, 1995; Levine et al., 1995).
Suppression of Kv1.5, however, occurs rapidly upon ex-
posure of cells to platelet-derived growth factor or fi-
broblast growth factor (Timpe and Fantl, 1994), and
similar acute exposure to EGF suppresses Kv1.2 (Per-
alta, 1995). In both of these examples, PLCg activation
is required for suppression, although it is not known
whether phosphorylation (tyrosine or otherwise) of the
channel is involved. 
Some of the effects of activation of the EGFr and the
Figure 7. Insulin treatment does not affect the inactivation rate.
Cells were transfected with Kv1.3. (A) Normalized traces from a
cell before (Control) and 10 min after (Insulin) addition of 10 mg/
ml insulin. (B) Mean inactivation rates of control cells and cells
pretreated for 10 min to 9 h with 10 mg/ml insulin. n 5 13 with
control cells and 10 with insulin-pretreated cells.608 Potassium Channel Modulation by Receptor Tyrosine Kinases
insulin receptor on Kv1.3 current levels reported here
may be due either to a change in channel activity or to
a reduced number of channels on the cell surface, or
both. Growth factor receptors internalize soon after ac-
tivation (reviewed by Schlessinger and Ullrich, 1992),
and this conceivably might result in nonspecific inter-
nalization of other membrane proteins, such as ion
channels. The decrease in current observed with growth
factor activation could be due in whole or in part to
such internalization of the channel. Similarly, the re-
versal of current suppression by a-EGFr may reflect a
larger amount of channel protein on the cell surface.
These putative internalization effects may not be de-
tectable on Western blots (unless internalization is cou-
pled with protein degradation), as this method mea-
sures protein in all compartments of the cell. However,
the acute effects of EGF and insulin that occur during a
patch recording are probably due to phosphorylation
of the channel and not to internalization since: (a) the
cell-attached patch is not exposed directly to EGF or in-
sulin and hence receptors in the patch, immediately
adjacent to the channels, do not bind ligand; and (b)
internalization of membrane from the patch probably
would disrupt the patch and interrupt the recording.
The effects of EGF and insulin may not all be due to
direct phosphorylation of the channel by the receptors,
especially given the fact that the patch of membrane
containing the channels is isolated from direct contact
Figure  8. EGF effects on peak
current amplitude and inactivation
rate are dissociable. Traces from
cell-attached patches from cells ex-
pressing (A) Kv1.3 Y137F, (B) Kv1.3
Y449F, (C) Kv1.3 YYY111-113FFF
and Y449F, or (D) Kv1.3 Y479F be-
fore (Control), and 25 min after
(EGF) acute treatment with EGF
(10 ng/ml) during patch record-
ing. In each case, the mutant chan-
nel was coexpressed with the EGFr.
(E) Mean decrease in current am-
plitude evoked by EGF for the four
channel mutants shown in A–D.
n 5 4 for each mutant. (F) Mean
increase in the inactivation rate
evoked by EGF for the four chan-
nel mutants shown in A–D. n 5 4
for each mutant.609 Bowlby et al.
with the ligand by the recording electrode. The modu-
latory process therefore is likely to be dependent on in-
tracellular factors in an endogenous signal transduc-
tion cascade. In the case of EGF, this cascade presum-
ably results in phosphorylation of Y479, which causes
the decrease in current amplitude, although serine/
threonine protein kinases may also be involved in the
pathway. In contrast to the effects on peak current, the
change in inactivation kinetics induced by the EGFr
may not be due to tyrosine phosphorylation of the
channel, as the inactivation change still occurs when
each of the tyrosine residues in good consensus sequences
for tyrosine kinases is mutated. Changes in inactivation
may be caused by phosphorylation of serine/threonine
residues or other tyrosine residues, or by other non–
phosphorylation-dependent mechanisms (e.g., Bowlby
and Levitan, 1995).
The EGFr is expressed widely, and its activation is
critical for signaling in many cell types (Threadgill et
al., 1995), including neurons (Morrison et al., 1987;
Kornblum et al., 1990). Activation of the EGFr in over-
expressing cell lines leads to activation of phospholi-
pase A2, activation of a voltage-independent calcium
channel, and calcium influx (Peppelenbosch et al.,
1991, 1992). This calcium influx leads, in turn, to acti-
vation of calcium-dependent potassium channels and
subsequent hyperpolarization of the cell resting poten-
tial (Pandiella et al., 1989; Magni et al., 1991). Funda-
mental aspects of cell physiology are affected greatly by
such fluctuations in the resting membrane potential.
The modulation of Kv1.3 current by EGFr or insulin re-
ceptor activation will generally increase cell excitability
and oppose any hyperpolarization-induced decrease in
excitability. Thus, complex integration of signals at the
level of individual ion channels could lead to changes
in growth rates, calcium influx, and a host of other cel-
lular phenomena.
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